Morgan Stanley analyst Simon Flannery lowered the firm’s price target on Anterix to $42 from $63 and keeps an Equal Weight rating on the shares after the company said that they would no longer provide specific timelines around contract signings, citing "the challenges of predicting contract timing." The firm, which pushed out its own estimates for contract signings, now projects about $500M in cumulative signed contract value by March 2024.
Published first on TheFly
